British Biotech Spin-Offs Get €40M Funding to Treat Narcolepsy
Orexia and Inexia, two new virtual companies spun out of Sosei Heptares, will develop drugs…
Orexia and Inexia, two new virtual companies spun out of Sosei Heptares, will develop drugs…
Richard Henderson, awarded the Nobel Prize in Chemistry 2017, founded Heptares Therapeutics to apply his Nobel-winning technology…
Allergan's partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat…
Heptares is expanding into a range of indications with its GPCR platform. I caught up…
Just 2% of experimental pain treatments clear Phase II. Why is this challenge so great,…
The UK biotech attacking notoriously evasive GPCRs has discovered a small molecule that could be…
Heptares Therapeutics has published the detailed structure and mechanism of action of a difficult-to-target GPCR…
Heptares Therapeutics has achieved a new milestone in its immuno-oncology collaboration with AstraZeneca triggering an…
Before the “who to recruit” phase, an important question is “where?” We ran through the…
Heptares Therapeutics and the University of Cambridge have partnered to investigate a novel target for…
Curious about which technologies have attracted the most cash in biotech finance this year? Here's a…
Heptares Therapeutics has acquired G7 Therapeutics to take control over its GPCR technology, boost its…